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Previous results suggest that GEM affects 5-fluorouracil (5-FU) metabolism and pharmacokinetics in cancer patients, while combined
with oxaliplatin, levo-folinic acid, and 5-FU (GOLF regimen), at doses achievable in cancer patients, determines high cytotoxic and
proapoptotic antitumour activity in colon cancer cells in vitro. On these bases we designed a phase I–II clinical trial testing the GOLF
regimen in patients with metastatic colorectal carcinoma, who had received at least a prior line of chemotherapy. In total, 29 patients
(20 males and nine females) enrolled in the study received every 2 weeks, gemcitabine (patients #1–3 received 600mgm
 2; patients
# 4–6 received 850mgm
 2; while patients # 7–29 received 1000mgm
 2) on the day 1, levo-folinic acid (100mgm
 2) on the days
1 and 2; 5-fluorouracil (400mgm
 2) in bolus injection, followed by a 22-h continuous infusion (800mgm
 2) on the days 1 and 2, and
oxaliplatin (85mgm
 2), 6h after the 5-FU bolus on day 2. The most frequent side effect was grade I–II haematological toxicity. In
total, 28 patients were evaluable for response: three achieved a complete response, nine a partial response, 10 had a stable disease,
and six progressed. The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months. Our
GOLF combination is well tolerated and seems promising for the treatment of advanced colorectal cancer.
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Colorectal carcinoma is the second leading cause of cancer death
in the Western countries and almost 50% of these patients die
because of problems related to disease progression. Although a
higher rate of response has been achieved with the newest
polychemotherapy regimens, patients with metastatic colorectal
cancer still have poor prognosis with a dismal 5-year survival rate
(Gill et al, 2003).
5-Fluorouracil (5-FU) alone or in combination with biomodu-
lators, such as folinic acid (FA), levamisol, interferon alpha, has
long been the only systemic treatment in adjuvant setting and
advanced stage of disease (Francini et al, 1994; Grem, 1996;
O’Connell, 1998; Von Hoff, 1998; Skibber, 2001), but new drugs
such as CPT-11 and the novel platinum derivative oxaliplatin have
recently been successfully combined with 5-FU in different
administration schedules and dosages (Skibber, 2001; Von Hoff,
1998). The combination of oxaliplatin with FA and infusional 5-FU
(FUFA) is currently being investigated by the American Food and
Drug Administration (FDA) in the first-line treatment for
advanced colorectal carcinoma. This new generation of drugs has
been evaluated in a number of clinical trials and has certainly
improved clinical response rates and survival; unfortunately, the
average overall survival still remain within the 20 months also in
the most optimistic studies (Grothey and Schmoll, 2001; Kohne,
2003; Goldberg et al, 2004; Tournigand et al, 2004).
The results of these trials, therefore, justify the continuing
search for new drugs or more active drug combinations. It has
been shown that the difluorinated analogue of deoxycytidine
known as gemcitabine (GEM) (difluoro-20,20-deoxycytidine) sy-
nergistically interacts with 5-FU in terms of antitumour activity in
colon carcinoma cells in vitro (Correale et al, 1999). The
combination of these two drugs administered by using different
schedules and dosages has also showed a significant antitumour
activity in patients with a different gastroenteric malignancies
(Berlin et al, 1998–1999; Schulz et al, 1998; Correale et al, 1999;
Hidalgo et al, 1999) including colo-rectal carcinoma (Madajewicz
et al, 2000). Previous studies of our group have in addition shown
a supra-additive cytotoxic activity and apoptosis-inducing capacity
of GEM combined with oxaliplatin and FUFA (GOLF) in colon
cancer cell lines in vitro (Correale et al, 2002 and unpublished
results). On these bases, we have designed a phase I–II clinical
trial aimed to investigate in patients with advanced colorectal
carcinoma who had received at least a line of chemotherapy, the
toxicity and the antitumour activity of a new polychemotherapy
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lregimen composed by GEM plus oxaliplatin and FUFA adminis-
tered using the schedule suggested by de Gramont et al (1997,
1998) (FOLFOX-4).
MATERIALS AND METHODS
Eligibility criteria
The inclusion criteria required a histological diagnosis of color-
ectal carcinoma, a Eastern Cooperative Oncology Group (ECOG)
performance status p2, a life expectancy 43 months, normal
renal and liver function, a white blood cell count 42500
cellsmm
 3, haemoglobin 49gdl
 1, platelet cell count 4100000
cellsmm
 3, a cardiac ejection fraction 446%, and a normal
electrocardiogram. The exclusion criteria included heart, liver or
kidney failure, cardiac valvular and wall motion abnormalities,
central nervous system involvement, second tumours, active
infectious disease, or a history of cardiovascular disease. The
study was approved by our local (University) ethics Committee,
and respected the guidelines for good clinical practice. All of the
patients gave their written informed consent.
The trial was designed to test the hypothesis that the GOLF
combination is tolerated and active in the treatment of colorectal
carcinoma. A minimum of 25 patients was required in order to
maintain an alpha and beta error of, respectively, 0.05 and 0.2. All
of the patients had previously received at least one line of
chemotherapy.
Clinical assessments
A complete history was taken, and a physical examination,
complete blood count, and serum chemistry evaluation were
performed at the baseline. Complete disease staging by chest X-
ray, chest and abdominal computed tomography, and liver and
pelvis ultrasonography was undertaken at the baseline and after
four, six and 12 treatment cycles. All of the eligible patients were
evaluated for survival and toxicity, and all of the patients were
considered evaluable for response. The patients continued the
treatment until the onset of unacceptable toxicity or disease
progression for a maximum of 18 cycles (9 months of treatment).
Response criteria
Response and toxicity were assessed according to standard World
Health Organization (1979) criteria.
RESULTS
Clinical trial design, patient characteristics, and treatment
schedule
This clinical trial involved patients with advanced colorectal
carcinoma, who had received at least one line of chemotherapy,
and was divided into two phases: the first was designed to test the
toxicity of the GOLF combination, and the second its antitumour
activity. The trial protocol foresaw early trial discontinuation in
the case of unacceptable toxicity or if no clinical response was
observed in the first 12 patients. In the first phase of the trial, three
groups of three patients each were administered standard doses of
oxaliplatin, FA, and 5-FU using the schedule proposed by de
Gramont et al (1997, 1998), and escalating doses of GEM. The
schedule of treatment was designed taking in consideration the
results of previous preclinical (Correale et al, 1999, 2002), and
pharmacokinetics (Correale et al, 2003) studies; thus all patients
received GEM, at different doses (see below) in a 30-min
intravenous (i.v.) infusion on day 1, before any other drug;
subsequently, they received levo-FA 100mgm
 2 in a 30-min i.v.
infusion on days 1 and 2; 5-FU 400mgm
 2 in a 30-min i.v.
infusion, followed by a 22-h continuous infusion (800mgm
 2)o n
days 1 and 2; and oxaliplatin 85mgm
 2 in a 2–4h i.v. infusion
before the second FUFA administration on day 2. The treatment
was repeated every 15 days.
A first group of three patients received GEM at the dosage of
600mgm
 2 (patients #1–3), a second group of three patients (#
4–6) received a dose of 850mgm
 2, and a third group (# 7–9)
received a dose of 1000mgm
 2. Previous studies, investigating the
two drug combination of GEM with 5-FA or with oxaliplatin in
different gastroenteric malignancies, suggest that the limiting dose
of GEM is 1000mgm
 2, thus in our study when this level of GEM
dose was reached in combination with oxaliplatinþFUFA without
the occurrence of significant side effects, all of the subsequently
enrolled patients, belonging to the phase II (patients #10–29),
received this dose of drug.
The trial population consisted of 29 patients (20 males and nine
females), with an average age of 67.7 year (range 42–77). They all
had a histological diagnosis of colorectal carcinoma, had under-
gone radical resection of the primary tumour, and were in
advanced stage of disease at the time of the enrolment. Their
ECOG performance status ranged from 0 and 2, and their life
expectancy was longer than 3 months. In total, 20 patients had
previously received one line of treatment, seven had received two
lines, and two had received three lines (Table 1).
Toxicity profile
A total of 296 chemotherapy cycles were administered (a median
range of 10 cycles per patient: range 6–18 cycles). No treatment
delay due to neutropenia or thrombocytopenia was required.
Moderate and severe asthenia was reported during the second
week of treatment. One patient experienced grade 3–4 gastro-
enteric toxicity with diarrhoea, and few cases of moderate
mucositis and vomiting were recorded after oxaliplatin adminis-
tration in the first cycle. Grade 1–2 haematological toxicity with
moderate anaemia, neutropenia, and thrombocytopenia was the
most common adverse event. No persistent thrombocytopenia was
observed after multiple cycles of chemotherapy. None of these
patients experienced increased creatinine or blood urea nitrogen,
Table 1 Clinical trial design
Characteristics Number of patients
Patients evaluable for response 28
Patients evaluable for toxicity 29
Sex
Male 20
Female 9
Performance status (ECOG) 0–2
Primary site
Sigma and left colon 21
Right colon 8
Stage IV 29 (100%)
Disease extension
(A) Liver 24
(B) No liver (bone+lung+peritoneum+ovary) 5
Previous treatments
Surgery 27
One line of chemotherapy 20
Two or more lines of chemotherapy 9
FUFA 23
IFL 7
FOLFOX-4 3
Raltitrexed 1
Intra-hepatic mytomicin C infusion 3
The median age of the patients was 67.7 year (range 42–77).
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lor hypotension. Three patients manifested reversible mucosal
toxicity, nausea/vomiting and diarrhoea, and two reversible grade
1–2 peripheral neurotoxicity. Three patients developed hypersen-
sitivity to oxaliplatin, and one of them had to be withdrawn from
the trial. There were no toxicity-related dose reductions or
treatment delays. Two days after the third cycle of treatment,
one patient developed a sudden gastric haemorrhage with
hypovolemic shock and eventually died for its consequences.
Two patients experienced reversible atrial fibrillation, one during
oxaliplatin administration and the other one 24h after the end of
the treatment. The first one of these two was the same patient who
showed hypersensitivity to oxaliplatin, while the second one had
this episode at the end of the 12th cycle of treatment (Table 2).
Response and survival
In total, 28 patients were evaluable for response: three achieved a
complete response, nine a partial response, 10 had a stable disease,
and six progressed. One patient was not evaluable for response due
to early toxicity related death. The time to progression and the
overall survival of each patient are reported in Table 3. Although
the follow-up is too short to provide definitive results, the clinical
response rate, the time to progression (7.26 months, 95% CI, I6–11
months), and the overall survival (22 months) seem to be
interesting, especially when compared with those obtained with
the most widely used second-line of treatments (Table 3).
DISCUSSION
Since its introduction by Heidelberger et al in 1957, 5-FU has been
one of the main components of treatments for the most common
malignancies. It is a prodrug that requires conversion by cancer
cells in the active metabolites, 5-fluorodeoxyuridine monopho-
sphate (5FdUMP) and 5-fluorouridine triphosphate (5FUTP) (Chu
et al, 2001). The most optimistic studies testing 5-FU for first-line
in colo-rectal carcinoma reported overall response rate lower than
15%, with a median survival of 12–18 months. Clinical evidence
suggests that the use of protracted intravenous infusion of 5-FU
may be more efficacious and better tolerated than bolus dosing
(Cancer, 1998), and that modulation of 5-FU may lead to higher
response rates (Poon et al, 1989, 1991). Oxaliplatin is a novel
diaminocyclohexane platinum agent that mainly acts by causing
inter- and intrastrand DNA crosslinks (Mathe et al, 1989; Soulie
et al, 1997; Wiseman et al, 1999; Culy et al, 2000). It has a wide
range of antitumour activity and promising effects in the treatment
of colorectal carcinoma (de Gramont et al, 1997, 1998; Wiseman
et al, 1999; Fischel et al, 1998, 2002). The potential benefit of
oxaliplatin plus FUFA (FOLFOX) over FUFA alone has been largely
demonstrated (de Gramont et al, 1998; Giacchetti et al, 2000;
Goldberg et al, 2002). More recently, based on the results of a NCI
clinical trial showing its superiority (in term of toleration,
objective response rate, time to progression, and overall survival)
over the CPT-11, FA, and 5-FU combination (IFL), the US FDA is
considering to expand the current indication of Oxali-FUFA (in
accord with the FOLFOX-4 schedule proposed by de Gramont) to
the first-line treatment for advanced colorectal carcinoma (Gold-
berg et al, 2002).
GEM is a difluoro-20,20-deoxycytidine that requires activation
through the synthesis of its phosphorylated metabolites (difluoro
deoxycytidine-diphosphate and triphosphate) in order to induce
DNA damage, to block the DNA repair system, and to affect the
deoxy-nucleotide synthesis (Plunkett et al, 1996; Chu et al, 2001).
On the basis of the first enthusiastic results of the early
preclinical and clinical studies mainly concentrated on NSCLC and
pancreas carcinoma, GEM moved very rapidly from phase I/II to
phase III trials (especially in combination with other established
anticancer drugs) leaving partially unexplored its activity in
several common cancers, such as colon and gastric carcinoma
(Plunkett et al, 1996; Grem et al, 1999; Heinemann, 2001). With the
exception of one abstract published at the ASCO meeting in the far
1992, single agent GEM antitumour activity in patients with
colorectal carcinoma has not been directly demonstrated. On the
other hand, previous studies have shown that GEM induces major
alterations in the pharmacodynamics, pharmacokinetics, and
antitumour activity of 5-FU that may lead to positive antitumour
results also in colon carcinoma patients (Berlin et al, 1998–1999;
Table 2 World Health Organization (WHO) toxicities (number of patients¼29)
Number of events (%) Grade 1 N (%) Grade 2 N (%) Grade 3 N (%) Grade 4 N (%)
Hematological 11 (37.9%)
Anaemia 4 (13.8%) 2 (6.9%) 2 (6.9%)
Neutropenia 6 (20.6%) 1 (3.45%) 2 (6.9%) 3 (10.3%)
Thrombocytopenia 1 (3.45%) 1 (3.45%)
Gastroenteric toxicity 7 (24.1%)
Nausea/vomiting 2 (6.9%) 1 (3.45%) 1 (3.45%)
Diarrhoea 2 (6.9%) 1 (3.45%) 1 (3.45%)
Mucositis 3 (10.3%) 2 (6.9%) 1 (3.45%)
Transaminase elevation None
Fever 8 (27.6%) 3 (10.3%) 5 (17.2%)
Asthenia 2 (6.9%) 1 (3.45%) 1 (3.45%)
Anorexia None
Neurological toxicity 2 2 (6.9%)
Arrythmia 2 2(6.9%)
Hypersensitivity 3 (10.3%) 1 (3.45%) 1 (3.45%) 1 (3.45%)
A total of 296 chemotherapy cycles were administered (a median range of 10 cycles per patient).
Table 3 Clinical response of advanced colorectal adenocarcinoma
patients to gemcitabine, oxaliplatin, and infusional levo-folinic acid and 5-
fluorouracil (GOLF) multidrug chemotherapy
Number PD CR PR SD NE
289 6 3 9 10 1
100% 20.7% 10.3% 31.2% 34.4% 3.4%
PD¼progressive disease; CR¼complete response; PR¼partial response;
SD¼stable disease; NE¼nonevaluable for response for early death. The time to
progression was 7.26 months (95% of CI 6.88–12.62). The overall survival was 22
months (95% CI 12.6–26.5).
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lSchulz et al, 1998; Correale et al, 1999, 2000a,b, 2003; Poplin et al,
1999; Madajewicz et al, 2000; Peters et al, 2000).
In more recent preclinical studies we also found that GEM, used
at concentrations potentially achievable in patients, is able to
enhance the cytotoxic and proapoptotic activity of oxaliplatin and
FUFA combination (Correale et al, 2000a,b, 2002, and unpublished
data). The antitumour effects of the GOLF regimen was far greater
than those induced by the combinations of GEM/5-FU, oxaliplatin/
GEM, or oxaliplatin/5-FU (unpublished results). In line with these
results, other groups also showed that oxaliplatin can have supra-
additive antitumour activity when used in combination with GEM
(Faivre et al, 1999; Mani et al, 2000; Raymond et al, 2001). This
effect, found in various tumour cell lines in vitro, has been
explained on the ground that GEM blocks the nuclear mechanisms
used by cancer cells to remove oxaliplatin adducts and to allow
DNA repair (Faivre et al, 1999; Mani et al, 2000; Raymond et al,
2001) with consequent induction of apoptosis. In the present trial,
the combined administration of GEM, oxaliplatin, and FUFA is
well tolerated and seems to have a high degree of antitumour
activity. With the exception of GEM, all of the drugs could be used
at full doses without the occurrence of significant side effects, and
their combination led to a high rate of objective responses
(CRþPR) (42%) and stable diseases (34.5%) with a time to
progression and an average survival, respectively, of 7.26 and 22
months. These results acquire greater importance if we consider
that the majority of the patients had previously received at least
one first-line of 5-FU-based treatment, and that the particular
design of the trial meant that the first six patients received
suboptimal doses of GEM and should, therefore, not be considered
in term of clinical response. In conclusion, the GOLF combination
seems promising for the treatment of advanced colorectal
carcinoma. It deserves to be studied in larger phase III clinical
trials in order to investigate its real impact on the survival of these
patients compared with the standard FOLFOX-4 regimen.
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